• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Greenwich LifeSciences Inc.

    11/1/24 4:45:14 PM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLSI alert in real time by email
    DEFA14A 1 formdefa14a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a)

    of the Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material Pursuant to § 240.14a-12

     

    Greenwich LifeSciences, Inc.
    (Name of Registrant as Specified in its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required

     

    ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

      (1) Title of each class of securities to which transaction applies:
         
      (2) Aggregate number of securities to which transaction applies:
         
      (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
         
      (4) Proposed maximum aggregate value of transaction:
         
      (5) Total fee paid:
         

     

    ☐ Fee paid previously with preliminary materials:

     

    ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

     

      (1) Amount Previously Paid:
         
      (2) Form, Schedule or Registration Statement No.:
         
      (3) Filing Party:
         
      (4) Date Filed:
         

     

     

     

     
     

     

     

     
     

     

     

     
     

     

     

     
     

     

     

     

     

    Get the next $GLSI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GLSI

    DatePrice TargetRatingAnalyst
    9/1/2021$78.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $GLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and CFO Patel Snehal bought $35,568 worth of shares (3,600 units at $9.88), increasing direct ownership by 0.06% to 5,570,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/29/25 6:14:15 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $48,492 worth of shares (5,400 units at $8.98), increasing direct ownership by 0.10% to 5,567,002 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/22/25 6:05:03 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $32,760 worth of shares (3,600 units at $9.10), increasing direct ownership by 0.06% to 5,561,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/8/25 6:05:08 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and CFO Patel Snehal bought $35,568 worth of shares (3,600 units at $9.88), increasing direct ownership by 0.06% to 5,570,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/29/25 6:14:15 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $48,492 worth of shares (5,400 units at $8.98), increasing direct ownership by 0.10% to 5,567,002 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/22/25 6:05:03 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $32,760 worth of shares (3,600 units at $9.10), increasing direct ownership by 0.06% to 5,561,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/8/25 6:05:08 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Greenwich LifeSciences Provides Global Update on FLAMINGO-01

      STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. The non-HLA-A*02 arm was expanded to 250 patients in 2024 with approval from both EU and US regulators. With t

      4/3/25 8:00:00 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

      STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types (non- HLA-A*02), show that GLSI-100 is creating an immune response over tim

      4/2/25 6:00:00 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

      STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modif

      3/27/25 6:00:00 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Greenwich LifeSciences Inc.

      10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

      5/20/25 4:30:30 PM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Greenwich LifeSciences Inc.

      NT 10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

      5/15/25 4:15:32 PM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Greenwich LifeSciences Inc.

      10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

      4/15/25 4:30:24 PM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Greenwich LifeSciences with a new price target

      HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00

      9/1/21 6:15:30 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital initiated coverage on Greenwich LifeSciences with a new price target

      Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

      1/27/21 6:00:07 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital initiated coverage on Greenwich LifeSciences with a new price target

      Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

      1/26/21 10:33:29 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Greenwich LifeSciences Inc.

      SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)

      6/22/22 11:53:43 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care